LY75 and Hodgkins lymphoma: Kato et al. have hypothesized that the binding between DEC205-ligand and DEC-205/DCL-1 fusion protein could activate a signaling pathway different from that of the DEC205 receptor [51] and suggested the fusion protein as a potential new target for antibody or T cell mediated immunotherapy for Hodgkin’s lymphoma.